

## Key data to be presented by Sobi at ERA 2025

VALIANT	
A thematic analysis of healthcare provider perspective on the care pathway and unmet needs in patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in the US and Europe. <i>Presenter: Carly Rich</i>	<b>Poster presentation</b> Session: <i>Glomerular &amp; tubulo-interstitial diseases</i> Room: XWall 1 Mozart Symphony No. 40 Date: 5 June 2025 Time: 13:12 CEST
Pegcetacoplan treatment effect in patients with nephrotic range proteinuria: results from the VALIANT Phase 3 study in patients with C3G or Primary (Idiopathic) IC-MPGN <i>Presenter: Antonio Mastrangelo</i>	<b>Oral presentation</b> Session: FC 14: <i>About C3 and IgA Glomerulonephritis</i> Room: Hall F1 Date: 6 June 2025 Time: 08:15 CEST
Targeted treatment with pegcetacoplan for adolescents with C3G or Primary (Idiopathic) IC-MPGN in the VALIANT Phase 3 trial <i>Presenter: Antonio Mastrangelo</i>	<b>Oral presentation</b> Session: <i>FC 14: About C3 and IgA Glomerulonephritis</i> Room: Hall F1 Date: 6 June 2025 Time: 08:30 CEST
Pegcetacoplan demonstrates clinically significant responses in C3G and Primary (Idiopathic) IC-MPGN patients with or without concomitant immunosuppression in VALIANT <i>Presenter: David Kavanagh</i>	<b>Oral presentation</b> Session: FC 14: <i>About C3 and IgA Glomerulonephritis</i> Room: Hall F1 Date: 6 June 2025 Time: 09:30 CEST
Association between proteinuria and clinically meaningful endpoints in patients with C3G / IC-MPGN: a Delphi consensus of European experts <i>Presenter: Fernando Caravaca-Fontán</i>	<b>Poster Presentation</b> Session: <i>Chronic Kidney Disease</i> Room: Strauss Wiener Blut Date: 6 June 2025 Time: 13:06 CEST
Pegcetacoplan for C3G and primary (idiopathic) IC-MPGN: 52-week results from the phase 3 VALIANT trial show sustained efficacy <i>Presenter: Fadi Fakhouri</i>	<b>Oral presentation</b> Session: <i>Innovative Kidney Trials</i> Room: The Square Date: 6 June 2025 Time: 15:00 CEST
Targeted Treatment with Pegcetacoplan for post-Transplant Recurrent C3G or Primary (idiopathic) IC-MPGN in the VALIANT Phase 3 Trial <i>Presenter: Michiel Oosterveld</i>	<b>Focused Oral presentation</b> Session: <i>Glomerular &amp; tubulo-interstitial diseases</i> Room: Focused Oral Room 3 Date: 6 June 2025 Time: 15:54 CEST
Pegcetacoplan Treatment appears to halt disease progression in C3G and Primary (Idiopathic) IC-MPGN patients: results from the Phase 3 VALIANT study <i>Presenter: Daniel Gale</i>	<b>Focused Oral presentation</b> Session: <i>Glomerular &amp; tubulo-interstitial diseases</i> Room: Focused Oral Room 3 Date: 6 June 2025 Time: 16:06 CEST